lactic acid has been researched along with Respiratory Insufficiency in 44 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Respiratory Insufficiency: Failure to adequately provide oxygen to cells of the body and to remove excess carbon dioxide from them. (Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the ability of four biomarkers (C-Reactive protein (CRP), lactate, mid-regional proadrenomedullin (MR-proADM) and procalcitonin (PCT)) to detect each kind of organ failure considered in the SOFA in 213 patients with infection, sepsis or septic shock, by using multivariate regression analysis and calculation of the area under the receiver operating curve (AUROC)." | 3.96 | MR- proADM to detect specific types of organ failure in infection. ( Aldecoa, C; Almansa, R; Andaluz-Ojeda, D; Andrés, C; Bermejo-Martin, JF; Calvo, D; Cicuendez, R; Esteban-Velasco, MC; Martín, S; Martin-Fernandez, M; Muñoz-Bellvís, L; Nogales, L; Ríos-Llorente, A; Sanchez-Barrado, E; Vaquero-Roncero, LM, 2020) |
| "D-lactic acidosis has been reported in patients after a variety of gastrointestinal surgeries, particularly jejunoileal bypass." | 3.77 | An extreme and life-threatening case of recurrent D-lactate encephalopathy. ( Htyte, N; Jones, J; Meisels, I; Sandhu, G; White, L, 2011) |
| " Reduced ATP and phosphocreatine content, intracellular acidosis related to hypercapnia, increased muscle lactate without alterations of the muscle lactate concentration gradient were observed in the skeletal muscle of the hypercapnic-hypoxemic COPD patients studied, in which group no correlation was found between hypoxia and energy or lactate metabolism parameters." | 3.67 | Skeletal muscle energetics, acid-base equilibrium and lactate metabolism in patients with severe hypercapnia and hypoxemia. ( Coffrini, E; Del Canale, S; Fiaccadori, E; Guariglia, A; Ronda, N; Vitali, P, 1987) |
| "Acute respiratory failure is a type of sepsis complicated by severe organ failure." | 1.91 | Development of a prognostic nomogram for sepsis associated-acute respiratory failure patients on 30-day mortality in intensive care units: a retrospective cohort study. ( He, Q; Luo, M, 2023) |
| "Respiratory failure was the most frequently observed complication (106 [67." | 1.62 | Identification of risk factors for in-hospital death of COVID - 19 pneumonia -- lessions from the early outbreak. ( Wang, Z, 2021) |
| "Cellular damage and cardiorespiratory failure are the most common causes of mortality and morbidity after poisoning." | 1.43 | Successful Treatment of Aluminium Phosphide Poisoning by Extracorporeal Membrane Oxygenation. ( Hajesmaeili, M; Hassanian-Moghaddam, H; Rahimi, M; Sadeghi, R; Taherkhani, M; Zamani, N, 2016) |
| "Hemolysis is common in all extracorporeal circuits as evident by the elevated plasma free hemoglobin (PFHb) level." | 1.42 | Plasma Free Hemoglobin Is an Independent Predictor of Mortality among Patients on Extracorporeal Membrane Oxygenation Support. ( Caldeira, C; Camporesi, EM; Mangar, D; Mirsaeidi, M; Omar, HR; Socias, S; Sprenker, C, 2015) |
| "Respiratory depression was measured using plethysmography." | 1.39 | Effects of monocarboxylate transporter inhibition on the oral toxicokinetics/toxicodynamics of γ-hydroxybutyrate and γ-butyrolactone. ( Morris, ME; Morse, BL, 2013) |
| "There are numerous ways to treat the respiratory insufficiency, but sometimes surgical intervention is needed." | 1.38 | Bioresorbable distraction device for the treatment of airway problems for infants with Robin sequence. ( Breugem, C; Kon, M; Mink van der Molen, AB; Paes, E; van der Molen, AB, 2012) |
| "There were 50 cases of type I respiratory failure and 60 cases of type II respiratory failure." | 1.36 | [Clinical significance of early lactate clearance rate in patients with respiratory failure]. ( Lin, Y; Zhao, YF; Zhu, XL, 2010) |
| "Opioids are known to induce respiratory depression." | 1.35 | Characteristics and comparative severity of respiratory response to toxic doses of fentanyl, methadone, morphine, and buprenorphine in rats. ( Baud, FJ; Chevillard, L; Mégarbane, B; Risède, P, 2009) |
| "Uncertainty exists as to whether pectus excavatum causes true physiologic impairments to exercise performance as opposed to lack of fitness due to reluctance to exercise." | 1.32 | Ventilatory and cardiovascular responses to exercise in patients with pectus excavatum. ( Cooper, CB; Fonkalsrud, EW; Malek, MH, 2003) |
| "Children with coma and respiratory distress (CM + RD) had greater evidence of renal dysfunction, lower mean pH and higher mean plasma osmolality than those with respiratory distress (RD) or coma (CM) as isolated findings (mean urea 10." | 1.30 | Acidosis in severe childhood malaria. ( English, M; Lowe, B; Marsh, K; Mosobo, M; Obiero, J; Sauerwein, R; Waruiru, C, 1997) |
| "In patients with acute respiratory failure under these circumstances, intravenous ketogenic emulsion therapy is worth consideration." | 1.30 | Adult leigh syndrome: treatment with intravenous soybean oil for acute central respiratory failure. ( Ichikawa, K; Kageyama, Y; Kumagai, R; Miyabayashi, S; Yasui, T, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (13.64) | 18.7374 |
| 1990's | 9 (20.45) | 18.2507 |
| 2000's | 10 (22.73) | 29.6817 |
| 2010's | 13 (29.55) | 24.3611 |
| 2020's | 6 (13.64) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, J | 1 |
| Zhong, Q | 1 |
| Luo, M | 1 |
| He, Q | 1 |
| Powell, EK | 1 |
| Reynolds, TS | 1 |
| Webb, JK | 1 |
| Kundi, R | 1 |
| Cantu, J | 1 |
| Keville, M | 1 |
| O'Connor, JV | 1 |
| Stein, DM | 1 |
| Hanson, MP | 1 |
| Taylor, BS | 1 |
| Scalea, TM | 1 |
| Galvagno, SM | 1 |
| Ren, J | 1 |
| Kang, Q | 1 |
| Wang, F | 1 |
| Yu, W | 1 |
| Andrés, C | 1 |
| Andaluz-Ojeda, D | 1 |
| Cicuendez, R | 1 |
| Nogales, L | 1 |
| Martín, S | 1 |
| Martin-Fernandez, M | 1 |
| Almansa, R | 1 |
| Calvo, D | 1 |
| Esteban-Velasco, MC | 1 |
| Vaquero-Roncero, LM | 1 |
| Ríos-Llorente, A | 1 |
| Sanchez-Barrado, E | 1 |
| Muñoz-Bellvís, L | 1 |
| Aldecoa, C | 1 |
| Bermejo-Martin, JF | 1 |
| Wang, Z | 2 |
| Sommerville, EW | 1 |
| Zhou, XL | 1 |
| Oláhová, M | 1 |
| Jenkins, J | 1 |
| Euro, L | 1 |
| Konovalova, S | 1 |
| Hilander, T | 1 |
| Pyle, A | 1 |
| He, L | 1 |
| Habeebu, S | 1 |
| Saunders, C | 1 |
| Kelsey, A | 1 |
| Morris, AAM | 1 |
| McFarland, R | 1 |
| Suomalainen, A | 1 |
| Gorman, GS | 1 |
| Wang, ED | 1 |
| Thiffault, I | 1 |
| Tyynismaa, H | 1 |
| Taylor, RW | 1 |
| Djordjevic, I | 1 |
| Sabashnikov, A | 1 |
| Deppe, AC | 1 |
| Kuhn, E | 1 |
| Eghbalzadeh, K | 1 |
| Merkle, J | 1 |
| Maier, J | 1 |
| Weber, C | 1 |
| Azizov, F | 1 |
| Sindhu, D | 1 |
| Wahlers, T | 1 |
| Morse, BL | 2 |
| Morris, ME | 2 |
| Omar, HR | 1 |
| Mirsaeidi, M | 1 |
| Socias, S | 1 |
| Sprenker, C | 1 |
| Caldeira, C | 1 |
| Camporesi, EM | 1 |
| Mangar, D | 1 |
| Roberts, JK | 1 |
| Disselkamp, M | 1 |
| Yataco, AC | 1 |
| di Grezia, F | 1 |
| di Panzillo, EA | 1 |
| Russo, S | 1 |
| Gargiulo, G | 1 |
| Della-Morte, D | 1 |
| Testa, G | 1 |
| Cacciatore, F | 1 |
| Bonaduce, D | 1 |
| Abete, P | 1 |
| Hassanian-Moghaddam, H | 1 |
| Zamani, N | 1 |
| Rahimi, M | 1 |
| Hajesmaeili, M | 1 |
| Taherkhani, M | 1 |
| Sadeghi, R | 1 |
| Avad, AS | 1 |
| Lutsenko, RV | 1 |
| Malyk, SV | 1 |
| Haginoya, K | 1 |
| Miyabayashi, S | 2 |
| Kikuchi, M | 1 |
| Kojima, A | 1 |
| Yamamoto, K | 1 |
| Omura, K | 1 |
| Uematsu, M | 1 |
| Hino-Fukuyo, N | 1 |
| Tanaka, S | 1 |
| Tsuchiya, S | 1 |
| Chevillard, L | 1 |
| Mégarbane, B | 1 |
| Risède, P | 1 |
| Baud, FJ | 1 |
| Zhao, YF | 1 |
| Lin, Y | 1 |
| Zhu, XL | 1 |
| Htyte, N | 1 |
| White, L | 1 |
| Sandhu, G | 1 |
| Jones, J | 1 |
| Meisels, I | 1 |
| Breugem, C | 1 |
| Paes, E | 1 |
| Kon, M | 1 |
| Mink van der Molen, AB | 1 |
| van der Molen, AB | 1 |
| Eddleston, M | 1 |
| Street, JM | 1 |
| Self, I | 1 |
| Thompson, A | 1 |
| King, T | 1 |
| Williams, N | 1 |
| Naredo, G | 1 |
| Dissanayake, K | 1 |
| Yu, LM | 1 |
| Worek, F | 1 |
| John, H | 1 |
| Smith, S | 1 |
| Thiermann, H | 1 |
| Harris, JB | 1 |
| Eddie Clutton, R | 1 |
| Sewall, GK | 1 |
| Warner, T | 1 |
| Connor, NP | 1 |
| Hartig, GK | 1 |
| Edwards, S | 1 |
| Malek, MH | 1 |
| Fonkalsrud, EW | 1 |
| Cooper, CB | 1 |
| BRUN, J | 2 |
| REVOL, A | 2 |
| BIOT, N | 2 |
| PERRIN-FAYOLLE, M | 1 |
| GARDERE, J | 1 |
| PENMAN, RW | 1 |
| Lin, VW | 1 |
| Hsiao, I | 1 |
| Deng, X | 1 |
| Lee, YS | 1 |
| Sasse, S | 1 |
| Gumanenko, EK | 1 |
| Nemchenko, NS | 1 |
| Goncharov, AV | 1 |
| Pashkovskiĭ, EV | 1 |
| Bohn, D | 1 |
| Hrabac, B | 1 |
| Schönhofer, B | 1 |
| Geibel, M | 1 |
| Wenzel, M | 1 |
| Rosenblüh, J | 1 |
| Köhler, D | 1 |
| Pandit, JJ | 1 |
| Robbins, PA | 1 |
| English, M | 1 |
| Sauerwein, R | 1 |
| Waruiru, C | 1 |
| Mosobo, M | 1 |
| Obiero, J | 1 |
| Lowe, B | 1 |
| Marsh, K | 1 |
| De Backer, D | 1 |
| Creteur, J | 1 |
| Zhang, H | 1 |
| Norrenberg, M | 1 |
| Vincent, JL | 1 |
| Zauner, A | 1 |
| Doppenberg, E | 1 |
| Soukup, J | 1 |
| Menzel, M | 1 |
| Young, HF | 1 |
| Bullock, R | 1 |
| Rabbat, A | 1 |
| Laaban, JP | 1 |
| Boussairi, A | 1 |
| Rochemaure, J | 1 |
| Kumagai, R | 1 |
| Ichikawa, K | 1 |
| Yasui, T | 1 |
| Kageyama, Y | 1 |
| Arbour, R | 1 |
| Esparis, B | 1 |
| Ciufo, R | 1 |
| Dimarco, A | 1 |
| Stofan, D | 1 |
| Nethery, D | 1 |
| Supinski, G | 1 |
| Jakobsson, EJ | 1 |
| Jorfeldt, L | 2 |
| Jakobsson, P | 1 |
| Brundin, A | 1 |
| Fiaccadori, E | 1 |
| Del Canale, S | 1 |
| Vitali, P | 1 |
| Coffrini, E | 1 |
| Ronda, N | 1 |
| Guariglia, A | 1 |
| Sadchikov, DV | 1 |
| Kutyreva, NV | 1 |
| Lugovskaia, TB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Feasibility Study to Consider the Relationship Between Markers of Red Cell Damage, Inflammation and the Recovery Process of Newborns Requiring Extracorporeal Membrane Oxygenation (ECMO) for Persistent Pulmonary Hypertension of the Newborn (PPHN): Mi-ECM[NCT02940327] | 24 participants (Actual) | Observational | 2016-02-19 | Completed | |||
| Aerobic Exercise to Improve Outcomes of Treatment for Methamphetamine Dependence[NCT01103531] | 135 participants (Actual) | Interventional | 2010-03-31 | Completed | |||
| Phase II Magnetic Alteration of Pectus Excavatum[NCT00466206] | Phase 1/Phase 2 | 10 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 24 hours after ECMO is discontinued
| Intervention | ml (Mean) |
|---|---|
| 7+ Days | 289.6 |
| <7 Days | 479.2 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 12 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 1.5 |
| <7 Days | 0.84 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 24 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 3.02 |
| <7 Days | 0.38 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 24 hours after ECMO decannulation
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 1.01 |
| <7 Days | 0.40 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 48 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 0.29 |
| <7 Days | 0.27 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 72 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 0.72 |
| <7 Days | 0.59 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 12 hours after ECMO commencement
| Intervention | percent change (Mean) |
|---|---|
| 7+ Days | 1.90 |
| <7 Days | 1.13 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 24 hours after decannulation
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 1.56 |
| <7 Days | 0.6 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 24 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 3.11 |
| <7 Days | 0.64 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 48 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 0.73 |
| <7 Days | 0.4 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 72 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 1.55 |
| <7 Days | 0.93 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 12 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 8.7 |
| <7 Days | 4.65 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 24 hours after decannulation
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 3.2 |
| <7 Days | 2.27 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 24 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 7.34 |
| <7 Days | 1.89 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 48 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 3.26 |
| <7 Days | 0.92 |
Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry. (NCT02940327)
Timeframe: 72 hours after ECMO commencement
| Intervention | percentage change (Mean) |
|---|---|
| 7+ Days | 3.31 |
| <7 Days | 1.9 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 12 hours after ECMO commencement
| Intervention | g/L (Mean) |
|---|---|
| 7+ Days | 109.64 |
| <7 Days | 112.07 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 24 hours after decannulation
| Intervention | g/L (Mean) |
|---|---|
| 7+ Days | 109.25 |
| <7 Days | 110.23 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 24 hours after ECMO commencement
| Intervention | g/L (Mean) |
|---|---|
| 7+ Days | 114.30 |
| <7 Days | 109.43 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 48 hours after ECMO commencement
| Intervention | g/L (Mean) |
|---|---|
| 7+ Days | 112.56 |
| <7 Days | 113.08 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 72 hours after ECMO commencement
| Intervention | g/L (Mean) |
|---|---|
| 7+ Days | 112.90 |
| <7 Days | 109.89 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: baseline
| Intervention | g/L (Mean) |
|---|---|
| 7+ Days | 151.5 |
| <7 Days | 145.4 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: > 7 days or did not survive to discharge
| Intervention | hours (Median) |
|---|---|
| 7+ Days | 292 |
| <7 Days | 80 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 12 hours after ECMO commencement
| Intervention | ng/ml (Mean) |
|---|---|
| 7+ Days | 7.89 |
| <7 Days | 6.96 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 24 hours after decannulation
| Intervention | ng/ml (Mean) |
|---|---|
| 7+ Days | 9.54 |
| <7 Days | 7.44 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 24 hours after ECMO commencement
| Intervention | ng/ml (Mean) |
|---|---|
| 7+ Days | 3.71 |
| <7 Days | 3.11 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 48 hours after ECMO commencement
| Intervention | ng/ml (Mean) |
|---|---|
| 7+ Days | 2.13 |
| <7 Days | 1.81 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 72 hours after ECMO commencement
| Intervention | ng/ml (Mean) |
|---|---|
| 7+ Days | 5.51 |
| <7 Days | 5.88 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: 24 hours after ECMO is discontinued
| Intervention | Participants (Count of Participants) |
|---|---|
| 7+ Days | 10 |
| <7 Days | 10 |
Clinical and biochemical markers of organ failure (NCT02940327)
Timeframe: >7 days or did not survive to discharge
| Intervention | participants (Number) |
|---|---|
| 7+ Days | 3 |
| <7 Days | 0 |
EKG performed prior to implantation, one month post-implantation, and after explanation to evaluate whether magnetic field near the heart adversely affects cardiac activity. Outcome measure describes number of patients who experienced adverse change in EKG. (NCT00466206)
Timeframe: One month post-explantation
| Intervention | participants (Number) |
|---|---|
| Magnetic Mini-Mover Group | 0 |
Outcome measure is number of patients who experienced permanent skin damage or discoloration due to external brace wear (NCT00466206)
Timeframe: One-month post-explant
| Intervention | participants (Number) |
|---|---|
| 3MP Treatment Group | 0 |
"Based on patient response to one-year post-explantation QoL statement: I would recommend this treatment for pectus excavatum (sunken chest) to someone else with pectus excavatum. Ratings: 5-strongly agree; 4-agree; 3-unsure; 2-disagree; 1-strongly disagree" (NCT00466206)
Timeframe: One year post-explanation
| Intervention | Scores on a scale (Mean) |
|---|---|
| Magnetic Mini-Mover Group | 4.2 |
Based on patient response to one-year post-explantation QoL questionnaire: How satisfied are you with the correction of your chest? Ratings: 5-very satisfied; 4-satisfied; 3-unsure; 2-dissatisfied; 1-very dissatisfied (NCT00466206)
Timeframe: One year post-explant
| Intervention | Scores on a scale (Mean) |
|---|---|
| 3MP Treatment Arm | 3.7 |
Compliance measured by average number of hours per day external device was worn by patient, as measured by the data sensor and logging device built into external prosthetic (NCT00466206)
Timeframe: 18 months active Rx
| Intervention | avg hours per day brace worn (Mean) |
|---|---|
| Treatment Arm | 16 |
1 review available for lactic acid and Respiratory Insufficiency
| Article | Year |
|---|---|
Cellular pathophysiology. Part 2: Responses following hypoxia.
Topics: Blood Volume; Calcium; Cell Membrane; Cell Physiological Phenomena; Energy Metabolism; Free Radicals | 2003 |
1 trial available for lactic acid and Respiratory Insufficiency
| Article | Year |
|---|---|
[FACTORIAL ANALYSIS IN PROGNOSTICATION OF INFECTIOUS COMPLICATIONS AFTER SIMULTANT OPERATIVE INTERVENTIONS FOR BILIARY CALCULOUS DISEASE].
Topics: Aged; Algorithms; Bacterial Infections; Blood Glucose; Cardiomegaly; Cholecystectomy, Laparoscopic; | 2016 |
42 other studies available for lactic acid and Respiratory Insufficiency
| Article | Year |
|---|---|
Analysis of prognostic factors for in-hospital mortality in patients with unplanned re-exploration after cardiovascular surgery.
Topics: Acute Kidney Injury; Creatinine; Female; Hospital Mortality; Humans; Lactic Acid; Male; Prognosis; R | 2022 |
Development of a prognostic nomogram for sepsis associated-acute respiratory failure patients on 30-day mortality in intensive care units: a retrospective cohort study.
Topics: Humans; Intensive Care Units; Lactic Acid; Nomograms; Prognosis; Respiratory Distress Syndrome; Resp | 2023 |
Early veno-venous extracorporeal membrane oxygenation is an effective strategy for traumatically injured patients presenting with refractory respiratory failure.
Topics: Extracorporeal Membrane Oxygenation; Hemodynamics; Humans; Lactic Acid; Respiratory Insufficiency; R | 2023 |
Association of lactate/albumin ratio with in-hospital mortality in ICU patients with acute respiratory failure: A retrospective analysis based on MIMIC-IV database.
Topics: Adult; Albumins; Critical Illness; Hospital Mortality; Humans; Intensive Care Units; Lactic Acid; Re | 2023 |
MR- proADM to detect specific types of organ failure in infection.
Topics: Adrenomedullin; Aged; Aged, 80 and over; Area Under Curve; Blood Coagulation Disorders; C-Reactive P | 2020 |
Identification of risk factors for in-hospital death of COVID - 19 pneumonia -- lessions from the early outbreak.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antivira | 2021 |
Instability of the mitochondrial alanyl-tRNA synthetase underlies fatal infantile-onset cardiomyopathy.
Topics: Alanine-tRNA Ligase; Cardiomyopathies; Diseases in Twins; Enzyme Stability; Fibroblasts; Genes, Rece | 2019 |
Risk factors associated with 30-day mortality for out-of-center ECMO support: experience from the newly launched ECMO retrieval service.
Topics: Adult; Aged; Cardiopulmonary Resuscitation; Extracorporeal Membrane Oxygenation; Female; Germany; He | 2019 |
Toxicokinetics/Toxicodynamics of γ-hydroxybutyrate-ethanol intoxication: evaluation of potential treatment strategies.
Topics: Animals; Central Nervous System Depressants; Conscious Sedation; Drug Overdose; Ethanol; GABA-B Rece | 2013 |
Plasma Free Hemoglobin Is an Independent Predictor of Mortality among Patients on Extracorporeal Membrane Oxygenation Support.
Topics: Aged; Biomarkers; Blood Transfusion; Cardiomyopathies; Extracorporeal Membrane Oxygenation; Female; | 2015 |
Oxygen Delivery in Septic Shock.
Topics: Aged; Anti-Bacterial Agents; Erythrocyte Transfusion; Fluid Therapy; Foot Ulcer; Gangrene; Hemodynam | 2015 |
Prognostic role of lactate on mortality in younger and older patients with cardio-respiratory failure admitted to an acute intensive care unit.
Topics: Acidosis, Lactic; Acute Coronary Syndrome; Aged; Female; Hospital Mortality; Hospitalization; Humans | 2016 |
Successful Treatment of Aluminium Phosphide Poisoning by Extracorporeal Membrane Oxygenation.
Topics: Adult; Aluminum Compounds; Echocardiography; Extracorporeal Membrane Oxygenation; Heart Failure; Hum | 2016 |
Efficacy of idebenone for respiratory failure in a patient with Leigh syndrome: a long-term follow-up study.
Topics: Adolescent; Brain Stem; Evoked Potentials, Auditory, Brain Stem; Follow-Up Studies; Humans; Lactic A | 2009 |
Characteristics and comparative severity of respiratory response to toxic doses of fentanyl, methadone, morphine, and buprenorphine in rats.
Topics: Animals; Blood Gas Analysis; Buprenorphine; Catheterization; Fentanyl; Lactic Acid; Male; Methadone; | 2009 |
[Clinical significance of early lactate clearance rate in patients with respiratory failure].
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Lactic Acid; Male; Metabolic Clearance Rate; Middle | 2010 |
An extreme and life-threatening case of recurrent D-lactate encephalopathy.
Topics: Acidosis, Lactic; Brain Diseases; Humans; Kidney Failure, Chronic; Lactic Acid; Male; Middle Aged; R | 2011 |
Bioresorbable distraction device for the treatment of airway problems for infants with Robin sequence.
Topics: Absorbable Implants; Airway Extubation; Airway Obstruction; Biocompatible Materials; Equipment Desig | 2012 |
A role for solvents in the toxicity of agricultural organophosphorus pesticides.
Topics: Agriculture; Animals; Cholinesterase Inhibitors; Cyclohexanones; Dimethoate; Emulsions; Humans; Inse | 2012 |
Effects of monocarboxylate transporter inhibition on the oral toxicokinetics/toxicodynamics of γ-hydroxybutyrate and γ-butyrolactone.
Topics: 4-Butyrolactone; Absorption; Administration, Oral; Animals; Dose-Response Relationship, Drug; Drug O | 2013 |
Comparison of resorbable poly-L-lactic acid-polyglycolic acid and internal Palmaz stents for the surgical correction of severe tracheomalacia.
Topics: Animals; Endoscopy; Granulation Tissue; Lactic Acid; Models, Animal; Polyesters; Polyglycolic Acid; | 2003 |
Ventilatory and cardiovascular responses to exercise in patients with pectus excavatum.
Topics: Adolescent; Adult; Cardiovascular Diseases; Exercise Test; Female; Forced Expiratory Volume; Funnel | 2003 |
Ventilatory and cardiovascular responses to exercise in patients with pectus excavatum.
Topics: Adolescent; Adult; Cardiovascular Diseases; Exercise Test; Female; Forced Expiratory Volume; Funnel | 2003 |
Ventilatory and cardiovascular responses to exercise in patients with pectus excavatum.
Topics: Adolescent; Adult; Cardiovascular Diseases; Exercise Test; Female; Forced Expiratory Volume; Funnel | 2003 |
Ventilatory and cardiovascular responses to exercise in patients with pectus excavatum.
Topics: Adolescent; Adult; Cardiovascular Diseases; Exercise Test; Female; Forced Expiratory Volume; Funnel | 2003 |
[Blood lactic acid in chronic respiratory insufficiency].
Topics: Humans; Lactates; Lactic Acid; Pulmonary Valve Insufficiency; Respiratory Insufficiency | 1962 |
[THE BLOOD LACTIC ACID DURING RESPIRATORY INSUFFICIENCY].
Topics: Blood Chemical Analysis; Bronchiectasis; Bronchitis; Humans; Lactates; Lactic Acid; Pneumoconiosis; | 1963 |
Blood lactate levels and some blood acidbase changes in respiratory failure and their significance in oxygen induced-respiratory depression.
Topics: Blood; Blood Chemical Analysis; Humans; Lactates; Lactic Acid; Oxygen; Respiratory Insufficiency; Re | 1962 |
Functional magnetic ventilation in dogs.
Topics: Analysis of Variance; Animals; Blood Gas Analysis; Carbon Dioxide; Cervical Vertebrae; Disease Model | 2004 |
[Pathogenetical features of the acute period of traumatic disease. Traumatic shock as a special manifestation of the acute period].
Topics: Abdominal Injuries; Acidosis; Acute Disease; Coma, Post-Head Injury; Disseminated Intravascular Coag | 2004 |
Metabolic acidosis in severe asthma: Is it the disease or is it the doctor?
Topics: Acidosis; Acute Disease; Albuterol; Asthma; Blood Gas Analysis; Bronchodilator Agents; Child, Presch | 2007 |
[The effect of corticosteroid therapy and global respiratory insufficiency on lactate and amino acid levels in the blood].
Topics: Amino Acids; Asthma; Humans; Lactates; Lactic Acid; Methylprednisolone; Respiratory Insufficiency | 1984 |
[Increase in hypercapnia in exercise--an unloading strategy?].
Topics: Adult; Carbon Dioxide; Exercise Test; Female; Home Care Services; Humans; Hypercapnia; Intermittent | 1995 |
The effect of exercise on the development of respiratory depression during sustained isocapnic hypoxia in humans.
Topics: Adult; Carbon Dioxide; Chemoreceptor Cells; Exercise; Humans; Hypoxia; Lactic Acid; Male; Oxygen; Re | 1997 |
Acidosis in severe childhood malaria.
Topics: Acidosis; Age Factors; Child, Preschool; Coma; Female; Hemoglobins; Humans; Infant; Lactic Acid; Mal | 1997 |
Lactate production by the lungs in acute lung injury.
Topics: Acute Disease; Animals; Cardiac Output; Female; Humans; Infant, Newborn; Lactic Acid; Lung; Lung Inj | 1997 |
Extended neuromonitoring: new therapeutic opportunities?
Topics: Adolescent; Adult; Body Temperature; Brain; Brain Chemistry; Carbon Dioxide; Cerebrovascular Circula | 1998 |
Hyperlactatemia during acute severe asthma.
Topics: Acidosis, Lactic; Acute Disease; Adult; Arteries; Asthma; Blood Gas Analysis; Disease Progression; F | 1998 |
Adult leigh syndrome: treatment with intravenous soybean oil for acute central respiratory failure.
Topics: Acute Disease; Adult; Diet; Fat Emulsions, Intravenous; Female; Humans; Injections, Intravenous; Ket | 1999 |
Osmolar gap metabolic acidosis in a 60-year-old man treated for hypoxemic respiratory failure.
Topics: Acidosis, Lactic; Drug Combinations; Humans; Hypnotics and Sedatives; Hypoxia; Infusions, Intravenou | 2000 |
Dichloroacetate reduces diaphragmatic lactate formation but impairs respiratory performance.
Topics: Airway Resistance; Analysis of Variance; Animals; Dichloroacetic Acid; In Vitro Techniques; Lactic A | 2001 |
Blood fuel metabolites at rest and during exercise in patients with advanced chronic obstructive pulmonary disease with and without chronic respiratory failure.
Topics: 3-Hydroxybutyric Acid; Alanine; Blood Glucose; Carbon Dioxide; Energy Metabolism; Fatty Acids, Nones | 1990 |
Skeletal muscle metabolites and fibre types in patients with advanced chronic obstructive pulmonary disease (COPD), with and without chronic respiratory failure.
Topics: Adenosine Triphosphate; Biopsy; Creatine; Female; Glycogen; Humans; Lactates; Lactic Acid; Lung Dise | 1990 |
Skeletal muscle energetics, acid-base equilibrium and lactate metabolism in patients with severe hypercapnia and hypoxemia.
Topics: Acid-Base Equilibrium; Acute Disease; Adenosine Triphosphate; Aged; Energy Metabolism; Female; Human | 1987 |
[Gas exchange and metabolic functions of the lungs in endotoxic shock].
Topics: Acidosis, Respiratory; Animals; Dogs; Female; Hydrogen-Ion Concentration; Hypoxia; Lactates; Lactic | 1985 |